Tenofovir amibufenamide
Based on 1 publication(s) in Google Scholar
Tenofovir amibufenamide (HS-10234), a Tenofovir prodrug, is an orally active antiviral agent. Tenofovir amibufenamide inhibits HBV, and can be used for chronic hepatitis B (CHB) study.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 1571076-26-0
- Formula: C22H31N6O5P
- Molecular Weight:490.49
-
Storage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tenofovir amibufenamide
More
Biological Activity
Tenofovir amibufenamide inhibits the HBV DNA replication with an EC50 of 7.3 nM in cell HepG2.2.15[3].
Tenofovir amibufenamide (5 μM, 3-9 days) corrects the metabolic disorders of host liver cells caused by HBV infection, including tricarboxylic acid cycle (TCA cycle), glycolysis, pentose phosphate pathway, purine/pyrimidine metabolism, amino acid metabolism, ketone body metabolism and phospholipid metabolism[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HBV transgenic mouse model[3]
-
Dosage:60.7 µmol/kg
-
Administration:po, once daily for 84 days
-
Result:Decreased the HBV DNA level in serum.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1571076-26-0
-
Appearance Solid
-
Molecular Weight 490.49
-
Formula C22H31N6O5P
-
Color Off-white to light yellow
-
SMILES
C[C@@H](OC[P@](OC1=CC=CC=C1)(NC(C)(C)C(OC(C)C)=O)=O)CN2C3=NC=NC(N)=C3N=C2
-
Synonyms
HS-10234
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Drug Metab Dispos
A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis. [Abstract]2026 Mar 2;54(5):100263. PMID: 42085925
Solvent & Solubility
DMSO : 200 mg/mL (407.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhihong Liu, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149. [Content Brief]
[2]. Hong Zhang, et al. Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection. Aliment Pharmacol Ther. 2021 Jan;53(2):243-252. [Content Brief]
[3]. Hong X, et al., Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front Pharmacol. 2022 Aug 29;13:932934. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0388 mL | 10.1939 mL | 20.3878 mL | 50.9694 mL |
| 5 mM | 0.4078 mL | 2.0388 mL | 4.0776 mL | 10.1939 mL | |
| 10 mM | 0.2039 mL | 1.0194 mL | 2.0388 mL | 5.0969 mL | |
| 15 mM | 0.1359 mL | 0.6796 mL | 1.3592 mL | 3.3980 mL | |
| 20 mM | 0.1019 mL | 0.5097 mL | 1.0194 mL | 2.5485 mL | |
| 25 mM | 0.0816 mL | 0.4078 mL | 0.8155 mL | 2.0388 mL | |
| 30 mM | 0.0680 mL | 0.3398 mL | 0.6796 mL | 1.6990 mL | |
| 40 mM | 0.0510 mL | 0.2548 mL | 0.5097 mL | 1.2742 mL | |
| 50 mM | 0.0408 mL | 0.2039 mL | 0.4078 mL | 1.0194 mL | |
| 60 mM | 0.0340 mL | 0.1699 mL | 0.3398 mL | 0.8495 mL | |
| 80 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.6371 mL | |
| 100 mM | 0.0204 mL | 0.1019 mL | 0.2039 mL | 0.5097 mL |
Tenofovir amibufenamide Related Classifications
HY-137453 Related Classifications
Powered by Bioz